CN119868364A - 用于治疗异常细胞生长的组合物和方法 - Google Patents

用于治疗异常细胞生长的组合物和方法 Download PDF

Info

Publication number
CN119868364A
CN119868364A CN202411889753.2A CN202411889753A CN119868364A CN 119868364 A CN119868364 A CN 119868364A CN 202411889753 A CN202411889753 A CN 202411889753A CN 119868364 A CN119868364 A CN 119868364A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
composition
acceptable salt
administered
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411889753.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·帕德瓦尔
P·O·坎萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Verastem Inc
Original Assignee
Pfizer Inc
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc, Verastem Inc filed Critical Pfizer Inc
Publication of CN119868364A publication Critical patent/CN119868364A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN202411889753.2A 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法 Pending CN119868364A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
US61/925,467 2014-01-09
CN201580011527.7A CN106102744A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580011527.7A Division CN106102744A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法

Publications (1)

Publication Number Publication Date
CN119868364A true CN119868364A (zh) 2025-04-25

Family

ID=52434976

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411889753.2A Pending CN119868364A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法
CN202211274002.0A Pending CN115708827A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法
CN201580011527.7A Pending CN106102744A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202211274002.0A Pending CN115708827A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法
CN201580011527.7A Pending CN106102744A (zh) 2014-01-09 2015-01-09 用于治疗异常细胞生长的组合物和方法

Country Status (15)

Country Link
US (3) US20150190346A1 (https=)
EP (2) EP3091981B1 (https=)
JP (5) JP6647204B2 (https=)
KR (3) KR102444494B1 (https=)
CN (3) CN119868364A (https=)
AU (4) AU2015204597B2 (https=)
BR (1) BR112016016021B1 (https=)
CA (1) CA2936283C (https=)
DK (1) DK3091981T3 (https=)
ES (1) ES2870562T3 (https=)
IL (2) IL246667B (https=)
MX (2) MX384259B (https=)
NZ (2) NZ721934A (https=)
SG (2) SG10201805890QA (https=)
WO (1) WO2015106096A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
EP4125896B1 (en) * 2020-03-27 2025-05-07 Pfizer Inc. Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
SI3965742T1 (sl) * 2020-04-24 2023-10-30 Dr. Falk Pharma Gmbh Sistemska formulacija piridinonskega derivata za bolezni, povezane s tg2
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
EP1653926A1 (en) * 2003-08-04 2006-05-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
MX2011001782A (es) * 2008-08-13 2012-02-08 Vertex Pharma Composicion farmaceutica y su administracion.
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2012027247A2 (en) * 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
EP2654726A1 (en) * 2011-03-08 2013-10-30 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法

Also Published As

Publication number Publication date
CN106102744A (zh) 2016-11-09
AU2020210153A1 (en) 2020-08-13
MX2016009056A (es) 2017-01-23
JP2017502062A (ja) 2017-01-19
CN115708827A (zh) 2023-02-24
AU2015204597B2 (en) 2020-04-30
JP2022001587A (ja) 2022-01-06
IL292054A (en) 2022-06-01
WO2015106096A1 (en) 2015-07-16
BR112016016021A8 (pt) 2018-04-17
NZ721934A (en) 2022-04-29
AU2020210153B2 (en) 2022-07-21
DK3091981T3 (da) 2021-05-31
ES2870562T3 (es) 2021-10-27
KR20240159639A (ko) 2024-11-05
IL246667A0 (en) 2016-08-31
AU2015204597A1 (en) 2016-07-21
MX384259B (es) 2025-03-14
BR112016016021B1 (pt) 2023-01-10
KR20220130251A (ko) 2022-09-26
EP3091981A1 (en) 2016-11-16
AU2025204843A1 (en) 2025-07-17
US20150190346A1 (en) 2015-07-09
EP3900726A1 (en) 2021-10-27
SG10201805890QA (en) 2018-08-30
CA2936283C (en) 2023-02-28
AU2022256144A1 (en) 2022-11-24
JP2020007355A (ja) 2020-01-16
US20230104303A1 (en) 2023-04-06
EP3091981B1 (en) 2021-03-10
AU2022256144B2 (en) 2025-04-03
JP6647204B2 (ja) 2020-02-14
IL246667B (en) 2022-05-01
KR20160104725A (ko) 2016-09-05
US20200038331A1 (en) 2020-02-06
BR112016016021A2 (pt) 2017-09-19
MX2021008225A (es) 2021-08-11
KR102444494B1 (ko) 2022-09-20
JP2023065568A (ja) 2023-05-12
NZ760233A (en) 2022-04-29
JP2025084892A (ja) 2025-06-03
SG11201605588YA (en) 2016-08-30
CA2936283A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
AU2022256144B2 (en) Compositions and methods for treatment of abnormal cell growth
TW201210591A (en) Oral dosage forms of bendamustine and therapeutic use thereof
US8741344B1 (en) Dispersible tablet
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
AU2013347264B2 (en) Dispersible tablet
HK40062771A (en) Compositions and methods for treatment of abnormal cell growth
HK1230942A1 (en) Compositions and methods for treatment of abnormal cell growth
US20150283083A1 (en) Dispersible Tablet
HK1230956B (en) Compositions and methods for treatment of abnormal cell growth
KR20260022394A (ko) 에스트로겐 수용체 분해제의 고형 경구제
DK177906B1 (en) Dispersible tablet
CN119365195A (zh) 含有匹米替比的医药组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination